One Therapy Instead of Years of Treatment: CAR-T Offers Hope for Multiple Myeloma

A new frontier in treating multiple myeloma is emerging with CAR-T cell therapy, offering hope for long-term remission rather than just extending life.

Historically, treatment for this blood cancer focused on prolonging patient survival. However, advancements are shifting the goal towards achieving years of remission without constant medical intervention. CAR-T therapy, which has already shown success in treating lymphomas and acute lymphoblastic leukemia, is now demonstrating significant promise for multiple myeloma.

Multiple myeloma develops in the bone marrow, gradually damaging the body and leading to issues like bone destruction, anemia, immune deficiencies, and kidney failure. In Poland, approximately 10,000 individuals live with the disease, with about 2,000 new diagnoses annually, predominantly among those over 50.

"This therapy is unique for two reasons. Firstly, it uses the patient's own immune system to fight cancer. Secondly, it is a one-time therapy. It offers the chance for a patient to receive treatment once and remain symptom-free for a long time," explained Dr. Wojciech Legieć, head of the Hematology and Bone Marrow Transplantation Department at the Oncology Center in Lublin. This potential for lasting remission after a single treatment is prompting many hematologists to reconsider treatment strategies for blood cancers.

While current therapies have transformed multiple myeloma into a chronic condition with significantly increased life expectancies, this often comes at the cost of continuous treatment. Patients typically remain on therapy as long as it is effective or until side effects become unmanageable, necessitating a switch to subsequent treatment lines. CAR-T therapy disrupts this cycle by offering a potentially curative, single-dose solution.

“

This therapy is unique for two reasons. Firstly, it uses the patient's own immune system to fight cancer. Secondly, it is a one-time therapy. It offers the chance for a patient to receive treatment once and remain symptom-free for a long time.